Cardiac structure and function and prognosis in heart failure with preserved ejection fraction

Amil M. Shah, Brian Claggett, Nancy K Sweitzer, Sanjiv J. Shah, Inder S. Anand, Eileen O'Meara, Akshay S. Desai, John F. Heitner, Guichu Li, James Fang, Jean Rouleau, Michael R. Zile, Valetin Markov, Vyacheslav Ryabov, Gilmar Reis, Susan F. Assmann, Sonja M. McKinlay, Bertram Pitt, Marc A. Pfeffer, Scott D. Solomon

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Background-Abnormalities in cardiac structure and function in heart failure with preserved ejection fraction may help identify patients at particularly high risk for cardiovascular morbidity and mortality. Methods and Results-Cardiac structure and function were assessed by echocardiography in a blinded core laboratory at baseline in 935 patients with heart failure with preserved ejection fraction (left ventricular ejection fraction ≥45%) enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial and related to the primary composite outcome of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest, and its components. At a median follow-up of 2.9 years, 244 patients experienced the primary outcome. Left ventricular hypertrophy (adjusted hazard ratio, 1.52; 95% confidence interval, 1.16'2.00), elevated left ventricular filling pressure (E/E'; adjusted hazard ratio 1.05 per 1 integer increase; 95% confidence interval, 1.02'1.07), and higher pulmonary artery pressure assessed by the tricuspid regurgitation velocity (hazard ratio, 1.23 per 0.5 m/s increase; 95% confidence interval, 1.02'1.49) were associated with the composite outcome and heart failure hospitalization alone after adjusting for clinical and laboratory variables. The risk of adverse outcome associated with left ventricular hypertrophy was additive to the risk associated with elevated E/E'.Conclusions-Among heart failure with preserved ejection fraction patients enrolled in TOPCAT, left ventricular hypertrophy, higher left ventricular filling pressure, and higher pulmonary artery pressure were predictive of heart failure hospitalization, cardiovascular death, or aborted cardiac arrest independent of clinical and laboratory predictors. These features, both alone and in combination, identify heart failure with preserved ejection fraction patients at particularly high risk for cardiovascular morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)740-751
Number of pages12
JournalCirculation: Heart Failure
Volume7
Issue number5
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Heart Failure
Left Ventricular Hypertrophy
Hospitalization
Ventricular Pressure
Confidence Intervals
Heart Arrest
Pulmonary Artery
Mineralocorticoid Receptor Antagonists
Morbidity
Pressure
Tricuspid Valve Insufficiency
Mortality
Stroke Volume
Echocardiography

Keywords

  • Clinical trial
  • Echocardiography
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. / Shah, Amil M.; Claggett, Brian; Sweitzer, Nancy K; Shah, Sanjiv J.; Anand, Inder S.; O'Meara, Eileen; Desai, Akshay S.; Heitner, John F.; Li, Guichu; Fang, James; Rouleau, Jean; Zile, Michael R.; Markov, Valetin; Ryabov, Vyacheslav; Reis, Gilmar; Assmann, Susan F.; McKinlay, Sonja M.; Pitt, Bertram; Pfeffer, Marc A.; Solomon, Scott D.

In: Circulation: Heart Failure, Vol. 7, No. 5, 01.09.2014, p. 740-751.

Research output: Contribution to journalArticle

Shah, AM, Claggett, B, Sweitzer, NK, Shah, SJ, Anand, IS, O'Meara, E, Desai, AS, Heitner, JF, Li, G, Fang, J, Rouleau, J, Zile, MR, Markov, V, Ryabov, V, Reis, G, Assmann, SF, McKinlay, SM, Pitt, B, Pfeffer, MA & Solomon, SD 2014, 'Cardiac structure and function and prognosis in heart failure with preserved ejection fraction', Circulation: Heart Failure, vol. 7, no. 5, pp. 740-751. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001583
Shah, Amil M. ; Claggett, Brian ; Sweitzer, Nancy K ; Shah, Sanjiv J. ; Anand, Inder S. ; O'Meara, Eileen ; Desai, Akshay S. ; Heitner, John F. ; Li, Guichu ; Fang, James ; Rouleau, Jean ; Zile, Michael R. ; Markov, Valetin ; Ryabov, Vyacheslav ; Reis, Gilmar ; Assmann, Susan F. ; McKinlay, Sonja M. ; Pitt, Bertram ; Pfeffer, Marc A. ; Solomon, Scott D. / Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. In: Circulation: Heart Failure. 2014 ; Vol. 7, No. 5. pp. 740-751.
@article{5017be87db20415db043e04f7030df78,
title = "Cardiac structure and function and prognosis in heart failure with preserved ejection fraction",
abstract = "Background-Abnormalities in cardiac structure and function in heart failure with preserved ejection fraction may help identify patients at particularly high risk for cardiovascular morbidity and mortality. Methods and Results-Cardiac structure and function were assessed by echocardiography in a blinded core laboratory at baseline in 935 patients with heart failure with preserved ejection fraction (left ventricular ejection fraction ≥45{\%}) enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial and related to the primary composite outcome of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest, and its components. At a median follow-up of 2.9 years, 244 patients experienced the primary outcome. Left ventricular hypertrophy (adjusted hazard ratio, 1.52; 95{\%} confidence interval, 1.16'2.00), elevated left ventricular filling pressure (E/E'; adjusted hazard ratio 1.05 per 1 integer increase; 95{\%} confidence interval, 1.02'1.07), and higher pulmonary artery pressure assessed by the tricuspid regurgitation velocity (hazard ratio, 1.23 per 0.5 m/s increase; 95{\%} confidence interval, 1.02'1.49) were associated with the composite outcome and heart failure hospitalization alone after adjusting for clinical and laboratory variables. The risk of adverse outcome associated with left ventricular hypertrophy was additive to the risk associated with elevated E/E'.Conclusions-Among heart failure with preserved ejection fraction patients enrolled in TOPCAT, left ventricular hypertrophy, higher left ventricular filling pressure, and higher pulmonary artery pressure were predictive of heart failure hospitalization, cardiovascular death, or aborted cardiac arrest independent of clinical and laboratory predictors. These features, both alone and in combination, identify heart failure with preserved ejection fraction patients at particularly high risk for cardiovascular morbidity and mortality.",
keywords = "Clinical trial, Echocardiography, Heart failure",
author = "Shah, {Amil M.} and Brian Claggett and Sweitzer, {Nancy K} and Shah, {Sanjiv J.} and Anand, {Inder S.} and Eileen O'Meara and Desai, {Akshay S.} and Heitner, {John F.} and Guichu Li and James Fang and Jean Rouleau and Zile, {Michael R.} and Valetin Markov and Vyacheslav Ryabov and Gilmar Reis and Assmann, {Susan F.} and McKinlay, {Sonja M.} and Bertram Pitt and Pfeffer, {Marc A.} and Solomon, {Scott D.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.114.001583",
language = "English (US)",
volume = "7",
pages = "740--751",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Cardiac structure and function and prognosis in heart failure with preserved ejection fraction

AU - Shah, Amil M.

AU - Claggett, Brian

AU - Sweitzer, Nancy K

AU - Shah, Sanjiv J.

AU - Anand, Inder S.

AU - O'Meara, Eileen

AU - Desai, Akshay S.

AU - Heitner, John F.

AU - Li, Guichu

AU - Fang, James

AU - Rouleau, Jean

AU - Zile, Michael R.

AU - Markov, Valetin

AU - Ryabov, Vyacheslav

AU - Reis, Gilmar

AU - Assmann, Susan F.

AU - McKinlay, Sonja M.

AU - Pitt, Bertram

AU - Pfeffer, Marc A.

AU - Solomon, Scott D.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Background-Abnormalities in cardiac structure and function in heart failure with preserved ejection fraction may help identify patients at particularly high risk for cardiovascular morbidity and mortality. Methods and Results-Cardiac structure and function were assessed by echocardiography in a blinded core laboratory at baseline in 935 patients with heart failure with preserved ejection fraction (left ventricular ejection fraction ≥45%) enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial and related to the primary composite outcome of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest, and its components. At a median follow-up of 2.9 years, 244 patients experienced the primary outcome. Left ventricular hypertrophy (adjusted hazard ratio, 1.52; 95% confidence interval, 1.16'2.00), elevated left ventricular filling pressure (E/E'; adjusted hazard ratio 1.05 per 1 integer increase; 95% confidence interval, 1.02'1.07), and higher pulmonary artery pressure assessed by the tricuspid regurgitation velocity (hazard ratio, 1.23 per 0.5 m/s increase; 95% confidence interval, 1.02'1.49) were associated with the composite outcome and heart failure hospitalization alone after adjusting for clinical and laboratory variables. The risk of adverse outcome associated with left ventricular hypertrophy was additive to the risk associated with elevated E/E'.Conclusions-Among heart failure with preserved ejection fraction patients enrolled in TOPCAT, left ventricular hypertrophy, higher left ventricular filling pressure, and higher pulmonary artery pressure were predictive of heart failure hospitalization, cardiovascular death, or aborted cardiac arrest independent of clinical and laboratory predictors. These features, both alone and in combination, identify heart failure with preserved ejection fraction patients at particularly high risk for cardiovascular morbidity and mortality.

AB - Background-Abnormalities in cardiac structure and function in heart failure with preserved ejection fraction may help identify patients at particularly high risk for cardiovascular morbidity and mortality. Methods and Results-Cardiac structure and function were assessed by echocardiography in a blinded core laboratory at baseline in 935 patients with heart failure with preserved ejection fraction (left ventricular ejection fraction ≥45%) enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial and related to the primary composite outcome of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest, and its components. At a median follow-up of 2.9 years, 244 patients experienced the primary outcome. Left ventricular hypertrophy (adjusted hazard ratio, 1.52; 95% confidence interval, 1.16'2.00), elevated left ventricular filling pressure (E/E'; adjusted hazard ratio 1.05 per 1 integer increase; 95% confidence interval, 1.02'1.07), and higher pulmonary artery pressure assessed by the tricuspid regurgitation velocity (hazard ratio, 1.23 per 0.5 m/s increase; 95% confidence interval, 1.02'1.49) were associated with the composite outcome and heart failure hospitalization alone after adjusting for clinical and laboratory variables. The risk of adverse outcome associated with left ventricular hypertrophy was additive to the risk associated with elevated E/E'.Conclusions-Among heart failure with preserved ejection fraction patients enrolled in TOPCAT, left ventricular hypertrophy, higher left ventricular filling pressure, and higher pulmonary artery pressure were predictive of heart failure hospitalization, cardiovascular death, or aborted cardiac arrest independent of clinical and laboratory predictors. These features, both alone and in combination, identify heart failure with preserved ejection fraction patients at particularly high risk for cardiovascular morbidity and mortality.

KW - Clinical trial

KW - Echocardiography

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=84920134990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920134990&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.114.001583

DO - 10.1161/CIRCHEARTFAILURE.114.001583

M3 - Article

C2 - 25122186

AN - SCOPUS:84920134990

VL - 7

SP - 740

EP - 751

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 5

ER -